Company Profile

Roche Holding AG

ROG · SW
Industry
Pharmaceuticals & Diagnostics
Exchange
SW
Current Price
322
Jun 5, 2026 close
Fair Buy
≤ 295
Margin-of-safety entry
Baillie Growth Score
36/100
Weak
Intrinsic Value · Three-Tier Range Current price 322 · Between the conservative and fair ranges

Composite valuation range · conservative 250–285 / fair 340–385 / optimistic 450–520. At 322, Between the conservative and fair ranges.

Research on this stock
Roche Holding AG
ROG · SW
Hold
Roche Zen Horizon Framework Deep Dive: A Diagnostics and Pharma Giant Past the Patent Cliff, with a Fair Price and Debated Growth

Roche is the global leader in in vitro diagnostics and a top-tier pharmaceutical company in oncology, neurology, and ophthalmology, with family control and CHF-denominated shares. The company has moved past its patent cliff, new medicines have filled an approximately USD 10 billion gap, and the group has returned to +7% constant-currency growth, though a strong Swiss franc has reduced reported growth to only +2% in CHF. Rating Hold: valuation is fair at roughly 16x forward PE with a 3% dividend, 27% below the 2022 high, while growth remains debated and obesity is the largest upside option.

Pharmaceuticals & Diagnostics Baillie 36 Jun 5, 2026
About the company

Company overview coming soon.

Background

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.